Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes

Journal of Biomedical Science

Volumn 10, Issue 5, 2003, Pages 552-564

  Yeh, Geng Chang ^a   Tao, Pao Luh ^b   Ho, Hsiu O ^c   Lee, Yung Jin ^d   Chen, Julia Yi Ru ^a   Sheu, Ming Thau ^c  

^a TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Dextromethorphan; Dextrorphan; Metabolic ratio; Pharmacokinetic parameters; Steady state

Indexed keywords

CYTOCHROME P450 2D6; DETUSIV; DEXTROMETHORPHAN; DEXTRORPHAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CALCULATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; DRUG HALF LIFE; DRUG METABOLISM; DRUG RELEASE; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHENOTYPE; STEADY STATE;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANTITUSSIVE AGENTS; AREA UNDER CURVE; DEXTROMETHORPHAN; DEXTRORPHAN; HUMANS; KINETICS; MALE; METABOLIC CLEARANCE RATE; PHENOTYPE; REFERENCE VALUES; VARIATION (GENETICS);

EID: 0041421280     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1159/000072383     Document Type: Article

References (25)

1. Ducharme J, Abdullah S, Wainer WI. Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. J Chromatogr B Biomed Appl 678:113-128;1996.
2. Edeki T. Clinical importance of genetic polymorphism of drug oxidation. Mt Sinai J Med 63:291-300;1996.
3. Engel G, Hofmann U, Kroemer HK. Prediction of CYP2D6-mediated polymorphic drug metabolism (sparteine type) based on in vitro investigations. J Chromatogr B Biomed Appl 678:93-103;1996.
4. Führ U, Rost KL. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics 4:109-116;1994.
5. Goldstein JA, Faletto MB, Romkes-Sparks M. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33:1743-1752;1994.
6. Gonzalez FJ, Skoda RC, Kimura S, et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331:442-446;1988.
7. Henthorn TK, Benitez J, Avram MJ. Assessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distributions analysis. Clin Pharmacol Ther 45:328-333;1989.
8. Horai Y, Nakano M, Ishizaki T, et al. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 46:198-207;1989.
9. Hou ZY, Chen CP, Yang WC, Lai MD, Buchert ET, Chung HM, et al. Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis. Clin Pharmacol Ther 59:411-417;1996.
10. Hou ZY, Pickle LW, Meyer RN, Woosley RL. Salivary analysis for determination of dextromethorphan metabolic phenotype. Clin Pharmacol Ther 49:410-419;1991.
11. Hu OY, Tang HS, Lane HY, Chang WO, Hun TM: Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity. J Pharmacol Exp Ther 285: 955-960;1998.
12. Jacqz-Aigrain E, Funck Brentano C, Cresteil T. CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 3:197-204;1998.
13. Kerry NL, Somogyi AA, Bochner F, Mikus G. The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: In vitro studies using human liver microsomes. Br J Clin Pharmacol 38:243-248;1994.
14. Kevorkian JP, Michel C, Hofmann U, et al. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: Comparison of sparteine and dextromethorphan. Clin Pharmacol Ther 56:583-592;1996.
15. Kivisto KT, Kroemer HH. Use of probe drugs as predictors of drug metabolism in humans. J Clin Pharmacol 37:40-48S;1997.
16. Köhler D, Härtter S, Fuchs K, Sieghart W, Hiemke C. CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication. Pharmacogenetics 7:453-461;1997.
17. Larrey D, Babany G, Tinel M, et al: Effect of liver disease on dextromethorphan oxidation capacity and phenotype: A study in 107 patients. Br J Clin Pharmacol 28:297-304;1989.
18. Meyer UA. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 37:269-296;1997.
19. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Venkatakrishnan K, Schmider J, Harmatz JS, Shader R: Multiple human cytochromes contribute to biotransformation of dextromethorphan in vitro: Role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. J Pharm Pharmacol 50:997-1004;1998.
20. Mortimer O, Lindström B, Laurell H, Bergman U, Rane A. Dextromethorphan: Polymorphic serum pattern of the O-demethylated and didemethylated metabolites in man. Br J Clin Pharmacol 27:223-227;1989.
21. 14C]dextromethorphan as substrate. Methods Enzymol 272:186-195;1996.
22. Rostami-Hodjegan A, Kroemer HK, Tucker GT. In vivo indices of enzyme activity: The effect of renal impairment on the assessment of CYP2D6 activity. Pharmacogenetics 9:277-286;1999.
23. Rostami-Hodjegan A, Nurminen S, Jackson PR, Tucker GT. Caffeine urinary metabolite ratios as markers of enzyme activity: A theoretical assessment. Pharmacogenetics 6:121-149;1996.
24. Schmid B, Bircher J, Preisig R, Kupfer A. Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38:618-624;1985.
25. Straka RJ, Hansen SR, Walker PF. Comparison of the prevalence of the poor metabolizer phenotype for CYP2D6 between 203 Hmong subjects residing in Minnesota. Clin Pharmacol Ther 58:29-34;1995.